Therapeutic advancement of chronic lymphocytic leukemia

Table 2 Selected trials of chemoimmunotherapy with rituximab in CLL patients

Reference (year)	Regimen	Phase	Number of patients	Treatment status	CR,%	ORR,%	Median PFS (months)	Median OS (months)
Woyach, 2011 [17]	FR (C)	2	51	Untreated	47	90	42	85
	FR (S)		53	Untreated	28	77
Kay, 2007 [18]	PCR	2	64	Untreated	41	91	32.6	Not Rep
Kay, 2010 [19]	PR	2	33	Untreated	27	76	12	Not Rep
Reynolds, 2011 [20]	PCR	3	92	20% Pretreated	7	49	NR	NR
	FCR		92	20% Pretreated	14	59	NR	NR
Wierda, 2011 [21]	FBR	1/2	14	Untreated	36	93	Not Rep	Not Rep
Bosch, 2011 [23]	R-FCM	2	72	Untreated	82	93	Not Rep	Not Rep
Jenke, 2011 [24]	CHOP-R	2	26	Pretreated, F-ref	0	54	11	27
			15	Pretreated, RT	7	67	15	27
			15	Pretreated, AIC	0	82	14	50

Abbreviations: AIC, autoimmune cytopenia; CHOP-R, cyclophosphamide, adriamycin, vincristine and prednisone plus rituximab; CR, complete response; FBR, fludarabine, bendamustine, and rituximab; FR (C), fludarabine, rituximab, concurrent; FR (S), fludarabine, rituximab, sequential; FCR, fludarabine, cyclophosphamide, rituximab; F-ref, fludarabine-refractory; NR, not researched; Not Rep, not reported; ORR, overall response rate; OS, overall survival; PCR, penostatin cyclophosphamide, rituximab; PFS, progression-free survival; R-FCM, rituximab, fludarabine, cyclophosphamide, mitoxantrone; RT: Richter’s transformation.

ISSN: 1756-8722